Yahoo Malaysia Web Search

Search results

  1. Regeneron is a biotech company that develops new medicines for serious diseases, such as cancer, asthma and COVID-19. Learn about their scientific breakthroughs, clinical trials, responsibility goals and career opportunities.

    • Scientists

      Rapid response to infectious diseases. How can we go even...

    • Patients

      Regeneron (NASDAQ: REGN) is a leading biotechnology company...

    • Medical Professionals

      Regeneron’s Compassionate Use Policy gives certain patients...

    • Investors and Media

      Regeneron Pharmaceuticals Q2 2024 Earnings Conference Call....

    • Careers

      Working at Regeneron. We are a team of original thinkers who...

    • Find Trials

      Regeneron is a biotechnology company that develops medicines...

    • Improving Lives

      Regeneron has supported advocacy training, distribution of...

    • About

      At Regeneron, we move science to medicine because our world...

  2. Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

  3. Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.

  4. Regeneron is a biotech company that invents and develops medicines for serious diseases, such as eye, allergic, inflammatory, cancer, and rare diseases. Founded and led by physician-scientists, Regeneron uses proprietary technologies and genetics sequencing to create life-transforming treatments.

  5. Regeneron is a biotechnology company with over 12,000 employees in 7 countries. Find out where they are located, how to contact them and how to report adverse events or product complaints.

  6. Find the latest Regeneron Pharmaceuticals, Inc. (REGN) stock quote, history, news and other vital information to help you with your stock trading and investing.

  7. May 31. Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation. May 23. Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO. May 20.